GLP1R and metabolic dysfunction-associated steatotic liver disease: The clinical practice guidelines for NAFLD/Metabolic dysfunction-associated fatty liver disease (MAFLD)/MASLD of several major societies of hepatology recommended the following anti-diabetic medications for NAFLD/MAFLD/MASLD patients with type 2 diabetes mellitus: thiazolidinediones, glucagon-like peptide-1 receptor agonist, and SGLT2I [88,89,90,91].